Zurzuvae PPD denied for missing prior authorization by Aetna?

Aetna's specific coverage criteria for zurzuvae ppd are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Requires Prior Authorization for Zurzuvae in PPD

Prior authorization (PA) for Zurzuvae (zuranolone) in postpartum depression is standard across most Aetna plans because the drug is newer, higher in cost, and placed on a restricted formulary tier. Aetna uses PA to verify that the clinical criteria in its coverage policy are met before approving coverage. A PA denial — or a denial resulting from a lapsed or absent PA — is one of the most common and most reversible types of pharmacy benefit denials.

## Why This Denial Is Appealable

If PA was denied, the denial is an adverse benefit determination subject to internal and external review under ACA §2719 and ERISA §503. If coverage was denied because no PA was submitted, the treating clinician can submit or refile the PA with complete documentation. Either way, you have the right to a full-and-fair review, and the standard is whether the requested treatment is medically necessary under the terms of your plan and the applicable clinical evidence.

## Federal Appeal Framework

• PA resubmission (if never filed or incomplete): Work with the prescriber's office to submit a complete PA request with all required clinical documentation before filing a formal appeal.
• Internal appeal of PA denial: If PA was filed and denied, appeal formally within the timeframe in the denial letter. The plan must respond within 15 days for pre-service (standard) or 72 hours (expedited).
• External review (ACA §2719): After exhausting internal appeals, request independent external review within approximately 4 months of the final internal denial.
• Expedited option: If delay would seriously jeopardize the patient's health — particularly relevant in the postpartum period — request expedited PA review and expedited external review simultaneously.

## Documentation to Gather

1. Complete PA package: Obtain Aetna's current PA criteria for Zurzuvae. Ensure the PA submission addresses every listed criterion with supporting documentation. 2. DSM-5 diagnosis documentation: Chart notes confirming a diagnosis of MDD with peripartum onset, including symptom onset timing relative to delivery. 3. Clinical severity evidence: Validated severity scale results documented in the chart, functional impairment notes, and any safety concerns. 4. Prior-treatment history: A complete documented history of antidepressants previously tried, with dates, dosing history (per medical record), and outcome — including reasons for discontinuation. 5. Medical-necessity letter: A detailed letter from the prescribing clinician or psychiatrist explaining why Zurzuvae is medically necessary for this patient, referencing the FDA-approved labeling and the relevant clinical guideline organization. 6. Denial letter and PA criteria: Obtain the specific reasons PA was denied and the full list of PA criteria from Aetna; map each to a chart-documented response in your appeal.

## Criteria-Mapping Structure

For each PA criterion Aetna listed as unmet or undocumented:

• Criterion (verbatim from Aetna PA form or denial letter): [paste exact language]
• Documentation provided: [chart note, date, clinician, and specific finding]

Attach all supporting records as labeled exhibits. If the prescriber's office submitted the PA, coordinate with them to ensure no criterion was left unanswered in the original submission.